-- Taxotere containing regimen reduces the risk of death by 28% in patients with inoperable locally advanced head and neck cancer --
Trots att hjärt- och kärlsjukdomar är den vanligaste dödsorsaken i Sverige informerar sällan läkare om de bakomliggande riskfaktorerna. Studien Shape of The Nations 2006 visar också att endast 17 % av de svenska allmänläkarna tar midjemått på sina patienter. Stort midjemått en av de tydligast påvisbara riskfaktorerna för hjärt- och kärlsjukdomar.
Dr. Heinz-Werner Meier appointed Senior Vice President, Human Resources to succeed Jean-Claude Armbruster
Sanofi-aventis announced today that it has taken the decision to withdraw the European application for Marketing Authorisation of dronedarone (MULTAQ), 400 mg film-coated tablets intended for use in the treatment of Atrial Fibrillation / Atrial Flutter.
- PLAVIX indication expanded to include patients with any acute coronary syndromes (ACS)-
Results of the PCI-ExTRACT-TIMI 25 study announced today at the World Congress of Cardiology-European Society of Cardiology 2006 in Barcelona.
För att driva sakfrågor och ytterligare förstärka sanofi-aventis roll inrättas en ny avdelning för Public Affairs.
Male osteoporosis: Neglected and Under Treated Paris, August 17, 2006 The US Food and Drug Administration (FDA) this week approved Actonel® 35mg (risedronate sodium tablets) for treatment to increase bone mass in men with osteoporosis
Sanofi-aventis and Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration has approved the supplemental new drug application for the antiplatelet agent PLAVIX® (clopidogrel bisulfate) to reduce the rate of death from any cause and the rate of a combined endpoint of re-infarction, stroke or death in patients with acute ST-segment elevation myocardial infarction.
The consolidated income statement for the first half of 2006 is provided in the appendices. 2006 first-half consolidated net income after minority interests was 2,381 million, compared with 1,087 million for the first half of 2005, after the impact of the accounting treatment of acquisitions (primarily the acquisition of Aventis) and restructuring costs (1,583 million after tax in 2006 and 1,8
Läs Sanofi-Aventis resultat för första hälften av 2006 i bifogade dokument.
Sanofi-aventis responded immediately on Tuesday evening to the call for medical assistance launched by the French Foreign Ministry, to offer support to Lebanon's health authorities and express solidarity with the people of Lebanon.
Måltidsinsulinet Apidra lanseras nu i en engångspenna. Pennan heter OptiSet och är förfylld med Apidra vilket underlättar för patienterna.
EU-kommissionen offentliggjorde igår att läkemedlet Acomplia® (rimonabant) godkänts för försäljning i samtliga EU-länder. Acomplia® är en ny och unik substans som påverkar ett flertal riskfaktorer för hjärtinfarkt och stroke. Sanofi-aventis räknar med att Acomplia® kommer att finnas tillgängligt på den svenska marknaden i början av 2007.
First-in-class CB1 blocker approved for the treatment of obese patients, or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidaemia
Behandling med insulin glargin ger låga blodsockernivåer och färre insulinkänningar med en tredjedel så många injektioner som behandling med insulin lispro. Detta visar Apollo-studien som redovisades på den årliga diabeteskongressen, American Diabetes Associations, ADA, som hölls i Washington D.C. i veckan.
Apollo study shows insulin glargine achieves HbA1c below 7% with less hypoglycemia, 3 times less insulin injections and less self-monitoring than the prandial analog lispro.
Type 2 Diabetes Patients Using a New Insulin Dosing Strategy Achieved a Mean A1C of 6.6% after 24 Weeks of Combination Therapy with Rapid-Acting Apidra® (insulin glulisine [rDNA origin] injection) and 24-hour Lantus® (insulin glargine [rDNA origin] injection).
Paris, France, June 7, 2006 Sanofiaventis announced today key trial results presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia, regarding the use of Taxotere® (docetaxel) regimens in the treatment of non small cell lung cancer (NSCLC), head and neck cancer and metastatic and adjuvant breast cancer.
Sanofiaventis announced today key results from three studies evaluating Eloxatin® (oxaliplatin injection) in various gastrointestinal tumor types (colorectal, pancreatic and gastric cancers). These results were presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia.